FGFR1 and infantile convulsions and choreoathetosis: Infigratinib, an inhibitor of FGFR1/3, was tested on advanced iCCA patients with FGFR2 gene fusions resistant to standard chemotherapy, showing an ORR of 31.0% and a confirmed ORR (cORR) of 26.9%, with the most common severe adverse events being hypophosphatemia, hyperphosphatemia, and hyponatremia [77].